Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group
Keywords: کارسینوم درجا; AD32; Superficial transitional cell carcinoma; Urothelial carcinoma; Carcinoma in situ; Bladder; Intravesical